In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?   

In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype RS into your decision? 



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Penn State Cancer Institute
In the same vein, how would you counsel patients o...
Medical Oncologist at Icahn School of Medicine at Mount Sinai
I would tell her there is no evidence for extendin...
Sign in or Register to read more